A large international pooled analysis of over twelve thousand men with prostate cancer adds substantial evidence that men who have higher circulating levels of vitamin D before their diagnosis tend to live longer after developing the disease. The study, which will be presented at AACR Annual Meeting 2026, focused on 25‑hydroxyvitamin D, the major blood […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This week the focus is on preclinical research. The fact that the AACR Annual Meeting 2026 is starting in less than a month means there are a lot of interesting new developments in the preclinical field. I’ll try to […]
JMKX007129 is a new small‑molecule drug that targets the N‑terminal domain (NTD) of the androgen receptor (AR) in prostate cancer. It is designed to overcome resistance seen with current AR‑ligand binding domain (LBD) inhibitors, which often stop working in castration‑resistant prostate cancer (CRPC) when AR develops mutations or produces splice variants like AR‑V7. JMKX007129 builds […]
AUTOTACs (Autophagy‑Targeting Chimeras), are molecules designed to force cancer cells to “clean up” and destroy the androgen receptor (AR), a key driver of prostate cancer growth and progression. The latest research on two second‑generation AR‑targeting AUTOTACs, ATB‑238 and ATB‑239, shows that these compounds can effectively degrade not only the normal AR but also its troublesome […]
RAX104 is a small molecule ligand designed specifically to target PSMA, the protein that is highly expressed on the surface of prostate cancer cells. When labeled with ²²⁵Ac, it forms a radioligand that combines the physical advantages of actinium‑225 (high linear energy transfer and a 10‑day half‑life) with a ligand engineered for better tumor retention. […]
HLX3902 is a STEAP1×CD3×CD28 trispecific T‑cell engager developed as a potential first‑in‑class immunotherapy for prostate cancer. Prostate tumors are largely “cold” from an immunological standpoint. The microenvironment is immunosuppressive, T cells are scarce inside the tumor mass, and those that do infiltrate often burn out quickly after activation. Classical CD3‑only bispecific TCEs can force T […]
Chemical‑induced proximity (CIP) strategies have expanded the therapeutic toolbox by modulating protein–protein interactions, but classical approaches such as PROTACs and molecular glues often force unnatural pairings or stabilize existing interfaces, leading to variable or unpredictable effects. Domain‑ALTeration Chimeras (DALTACs) take a different path: instead of degrading targets or reinforcing native contacts, they selectively miswire endogenous […]
A new experimental drug called TBI‑001 targets a protein called TRIB2 in advanced prostate cancer that has become resistant to hormone therapy and starts acquiring neuroendocrine features. This is particularly relevant for treatment‑emergent neuroendocrine prostate cancer (t‑NEPC), a lethal subtype that arises after long‑term androgen‑receptor–targeted therapy, loses dependence on AR signaling, and adopts a neuroendocrine […]
Most prostate cancer treatments today target the part of the AR protein that binds hormones, known as the ligand‑binding domain or LBD. At first these drugs like enzalutamide and abiraterone can shrink tumors or slow progression, but over time the cancer adapts and becomes resistant. This adaptation is a major reason why men with mCRPC […]
A novel approach to targeting androgen receptor signaling in prostate cancer is emerging with FX‑111, an experimental degrader that selectively removes the hormone‑bound, transcriptionally active form of the receptor known as ARon. In metastatic castration‑resistant prostate cancer (mCRPC), the androgen receptor remains a central driver in the vast majority of cases, yet resistance to current […]